Content uploaded by Michele Fornaro
Author content
All content in this area was uploaded by Michele Fornaro
Content may be subject to copyright.
© 2013 Fornaro et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2013:9 243–251
Neuropsychiatric Disease and Treatment
Adjunctive agomelatine therapy in the treatment
of acute bipolar II depression: a preliminary open
label study
Michele Fornaro1
Michael J McCarthy2,3
Domenico De Berardis4
Concetta De Pasquale1
Massimo Ta b aton5
Matteo Martino6
Salvatore Colicchio7
Carlo Ignazio Cattaneo8
Emanuela D’Angelo9
Pantaleo Fornaro6
1Department of Formative Sciences,
University of Catania, Catania, Italy;
2Department of Psychiatry, Veteran’s
Affairs San Diego Healthcare System,
3University of California San Diego,
La Jolla, CA, USA; 4Department of
Mental Health, Psychiatric Service
of Dia gno sis an d T rea tme nt,
“ASL 4”, Teramo, Italy; 5Department
of Internal Medicine and Medical
Specialties, University of Genova,
Genoa, Italy; 6Department of
Neurosciences, Section of Psychiatry,
University of Genova, Genoa, Italy;
7Unit of Sleep Medicine, Department
of Neuroscience, Catholic University,
Rome, Italy; 8National Health System,
“ASL 13”, Novara, Italy; 9National
Health System, “ASL 3”, Genoa, Italy
Correspondence: Michele Fornaro
Department of Formative Sciences at
the University of Catania, Via Teatro
Greco, 84, 95124, Catania, Italy
Tel 39-347-4140003
Fax 39-095-316792
Email dott.fornaro@gmail.com
Purpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for mela-
tonin in regulating mood, thus extending the interest toward the melatonergic antidepressant
agomelatine as well as type I (acute) or II cases of bipolar depression.
Patients and methods: Twenty-eight depressed BD-II patients received open label ago-
melatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or
valproate, followed by an optional treatment extension of 30 weeks. Measures included the
Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression
Scale–Bipolar Version, Young Mania Rating Scale, and body mass index.
Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed
medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects
(86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of
the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the first
endpoint. At 36 weeks, 14 valproate treated (82.4%) and 10 lithium treated (90.9%) subjects
responded. At 36 weeks, there was a slight yet statistically significant (P = 0.001) reduction in
body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline
values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four
patients (14.28%) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced
hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively.
Week 36 drop outs were two hypomanic cases, one per group.
Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/
lithium for acute depression in BD-II, suggesting the need for confirmation by future double
blind, controlled clinical trials.
Keywords: bipolar disorder type-II, acute bipolar depression, agomelatine, adjunctive
treatment
Introduction
Although the Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition
(DSM-IV)1 proposes mania as the hallmark of bipolar disorder (BD), depression
is the most enduring aspect of the illness,2 requiring intense treatment efforts.3
Moreover, the majority of patients with bipolar depression fail to respond adequately
to pharmacotherapy.4 For this reason, novel treatments for bipolar depression are
needed, and despite being controversial due to the uneven results reported in acute
and long-term follow-up clinical trials, antidepressant medications are commonly
used for bipolar depression.5 The antidepressant agomelatine is a norepinephrine and
dopamine disinhibitor drug, acting as a 5-HT2C/2B serotonin receptor antagonist and
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 243
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.S41557
Number of times this article has been viewed
This article was published in the following Dove Press journal:
Neuropsychiatric Disease and Treatment
14 February 2013
Neuropsychiatric Disease and Treatment 2013:9
MT1/MT2 melatonin receptor agonist proven effective in the
treatment of major depressive disorder (MDD).6–9
In pilot studies of type I BD (BD-I), agomelatine showed
interesting results.10,11 Yet, to the best of our knowledge, no
equivalent information has been provided about depression
in type II BD (BD-II). Because there are important dif-
ferences between BD-I and BD-II in terms of prevalence,
clinical course, and antidepressant treatment implications,
the use of agomelatine in the latter condition also warrants
investigation.
The conceptualization of BD as a disorder of cycling,
possibly based on disturbances in circadian rhythms, has been
suggested for centuries. Reports of impaired daily rhythms in
“emotional disturbances” date back to Hippocrates, Galen,
Aretaeus of Cappadocia [“…vital tone was subject to typical
circadian variations”], and later Kraepelin.12 However, it was
not until after the discovery of melatonin in 1958 that the link
between the pineal gland and affective disorders, considered
by 17th century Cartesian theorists, found scientific biologi-
cal support.13 More recently, these observations have been
articulated into specific hypotheses of circadian rhythms as
the bases for mood disorders.14,15 Presently, changes in sleep
are included in the DSM-IV criteria for major depressive
episodes, including those associated with BD, and sleep
patterns have been proposed as predictors of manic relapses
in BD.16 Melatonergic modulation has been shown to be
relevant in regulating circadian rhythms and sleep patterns,
both in MDD17,18 and BD,19 and recent evidence suggests an
association between 5HTR2C gene polymorphisms and BD.20
Therefore, the circadian rhythm system represents a rational
target for novel antidepressant medications aiming to address
these clinical features of BD,21 and due to its unique receptor
binding profile, considerable interest has been generated
around the use of agomelatine.
The principal aim of this open label pilot study was to
assess the efficacy and safety of adjunctive agomelatine
pharmacotherapy in the treatment of acute major depression
in BD-II. As secondary aims, we examined whether there
were differences in sleep and/or body mass associated with
agomelatine treatment, and whether any of these outcomes
were differentially associated with concomitant lithium or
valproate therapy.
Methods
Participants
Participants aged 18–65 years old were recruited by five
experienced physicians between November 2010 and May
2012 through referrals to two main private outpatient practice
centers in Italy (Genoa and Pisa). Patients were referred by
general practitioners, psychiatrists, or self-referral. All met
the DSM-IV criteria for a primary diagnosis of BD-II and
a current major depressive episode, assessed by the means
of the Structured Clinical Interview for DSM-IV Axis-I
Disorders.22 Additional inclusion criteria were a Hamilton
Depression Rating-Scale 17-item (HAM-D-17)23 baseline
score $ 18; negative history for adrenal, thyroid, or liver
diseases; and continuously therapeutic blood levels of
lithium or valproate for at least 6 months. Exclusion criteria
included (I) lifetime diagnosis of BD-I, schizophrenia, or
other psychotic disorders, rapid-cycling or seasonal pat-
terns, history of treatment-resistant depression (defined
as non-response to two consecutive treatments of at least
4 weeks each with two different classes of antidepressants),
Axis-II comorbidity (including mental retardation), and
alcohol/drug use disorders; (II) severe medical comorbidi-
ties, including organic brain syndrome, clinically significant
drug interactions (eg, ciprofloxacin), pregnancy, nursing, or
a woman of childbearing potential who declined the use of
an adequate contraceptive; (III) concomitant use of another
mood altering medication in the previous 2 weeks, or 4 weeks
in the case of fluoxetine (low doses of benzodiazepines [eg,
lorazepam # 2.5 mg/day] were allowed during the first
2 weeks); and (IIII) concomitant psychological treatment.
Written informed consent was obtained from all patients
prior to enrollment in the study after procedures had been
fully explained by a senior study coordinator active in
patients’ recruitment and evaluation. A total of 50 subjects
were initially screened, and 28 were enrolled in the study
(F/M = 17/11). Excluded cases included those with sub-
optimal mood stabilizer blood levels (n = 16), those using
concomitant pharmacotherapies not allowed by the study
protocol (n = 5), and those with a serious medical illness
( Gilbert’s syndrome, n = 1). Of the 28 subjects who partici-
pated, 17 (60.7%) were on valproate and 11 (39.3%) were
taking lithium as their primary mood stabilizer therapy.
Study design
The efficacy of agomelatine as an adjunct to valproate
(blood levels of 50–125 µg/ml) or lithium (blood levels
0.6–1.1 mmol/L) in the treatment of an acute BD-II major
depressive episode was addressed using a 6 week open
parallel-group design. No blind assessment or placebo con-
trols were adopted, and the patients were regularly monitored
for safety, with clear instructions to report any unexpected
adverse events (AEs), including mood changes, to their treat-
ing physician at the earliest possible time.
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
244
Fornaro et al
Neuropsychiatric Disease and Treatment 2013:9
Pharmacotherapy
A fixed dose of agomelatine was used during the entire
study (25 mg at bedtime: 9:00–10:00 pm). Higher doses
(eg, 50 mg/day) were excluded due to the preliminary nature
of the study according to safety considerations. During the
initial period of 6 weeks, a psychiatrist performed clinical
evaluations every 2 weeks on each subject. Thereafter, the
patients who continued the trial were evaluated every 6 weeks
until week 36.
Clinical assessment
Demographic and clinical characteristics were recorded at
baseline; the HAM-D-17 was the primary measure of mood.
In all cases, “response” was defined as .50% decrease in
severity from the baseline HAM-D-17 score. Secondary
measures were the Severity and Impression modules of the
Clinical Global Impression Scale–Bipolar Version 24 starting
at the second week, the Young Mania Rating Scale (YMRS),25
and the Pittsburgh Sleep Quality Index (PSQI),26 which is a
self-report instrument used to subjectively measure sleep
across seven domains: quality, latency, duration, efficiency,
disturbances, use of medication, and daytime somnolence.
The scale is designed to assess both the initial quality and
ongoing comparative measurements of sleep quality, and has
a reliability Cronbach’s alpha = 0.83.
At every appointment, an assessment, including general
and psychiatric clinical examinations, was performed. These
included measurements of blood pressure, heart rate, and
body mass index (BMI). Routine laboratory tests included
monitoring of liver functioning (safety, including liver
enzyme levels, was a secondary endpoint of the study) and
blood levels of lithium or valproate. All AEs experienced
by participants were recorded at each study visit, based
on the clinical judgment of the investigator(s). Due to the
explorative nature of the study and safety considerations,
whenever an AE occurred (any degree of severity), this was
considered grounds for agomelatine discontinuation by the
investigators. In these cases, subjects were excluded from
further study.
Statistical analysis
The a priori sample size requirement for the study was
calculated to be at least 12 in each of the two mood sta-
bilizer groups ($24 patients in total), based on consid-
erations described previously for non-randomized pilot
studies.27 All statistical analyses were performed using
IBM® SPSS®Statistics®v.21.0.0 for Microsoft® Windows®8
Release Preview, Build 8400. Since data followed a normal
distribution, they were assessed using the Shapiro-Wilk
test. Parametric comparative analysis for demographic,
clinical, and course characteristics of the two groups were
performed using a Student’s two-tailed t-test for the con-
tinuous variables, and χ2 analysis for categorical variables,
performing bivariate correlation analysis for selected metrics.
Significance was set at P , 0.05. Intent to treat analysis was
performed for efficacy in those patients who took at least one
capsule of study medication and had at least one valid post-
baseline efficacy evaluation, either on the study medication
or within 3 days of drug discontinuation.
Results
Patient characteristics
Baseline demographic and clinical characteristics of the study
subjects are shown in Table 1. There were no significant dif-
ferences in patient characteristics between the lithium and
valproate treated subjects, although some numerical differences
may have led to statistical significance with a larger, “non-
pilot,” sample size. All were diagnosed with BD-II, but many
had secondary psychiatric disorders. Inter-rater reliability on the
DSM-IV diagnosis indicated substantial agreement among the
raters (Cohen’s κ = 0.75 [P , 0.0001], 95% CI = 0.65–0.37).
By adopting a conservative definition of severe depression
of HAM-D-17 scores . 2828, it was found that five patients
(17.9%) were severely depressed at study entry (n = 4 [23.5%]
for valproate and n = 1 [9.1%] for lithium).
Primary outcomes
Using intent to treat analysis, 12 of the 17 valproate treated
(70.6%) and 6 of the 11(54.5%) lithium treated patients
demonstrated clinical response to agomelatine augmenta-
tion at the 6 week primary study endpoint. Six valproate and
one lithium treated patients (25% of the total) responded as
early as the second week of treatment. Secondary analyses
conducted at the 6 week assessment are shown in Table 2.
At the 36 week endpoint, 14 of the 17 (82.4%) valproate
treated and 10 of the 11 (90.9%) lithium treated subjects had
a clinical response.
Secondary outcomes
PISQ scores were significantly reduced after 6 weeks com-
pared to baseline (t = 6.738 [27]; P , 0.001), and PISQ scores
remained lower at week 36 (t = 3.777 [27]; P = 0.001). The
PISQ reduction was similar in both the valproate and lithium
groups, and occurred independently of therapeutic response at
weeks 6 or 36. At week 36, a slight yet statistically significant
(t = 3.777; df = 27; P , 0.001) reduction in BMI score was
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
245
Agomelatine adjunct in acute BD-II depression
Neuropsychiatric Disease and Treatment 2013:9
Table 1 Baseline characteristics of the patients included in the study
Included set
N = 28
Agomelatine +
valproate group
N = 17 (60.7%)
Agomelatine +
lithium group
N = 11 (39.3%)
F or χ2
(df = 2)
P
Sex F/M 17/11 9/8 8/3 0.295 (1) ns
Age in years,
Mean (SD); (range)
41.29 ± 13.60
(21–64)
41.94 ± 13.94
(23–64)
40.27 ± 13.66
(21–61)
0.174 ns
Age at rst diagnosis of BD,
mean (SD); (range)
26.21 ± 9.79
(13–59)
25.58 ± 7.68
(13–42)
27.18 ± 12.76
(14–59)
1.539 (26) ns
BMI score, mean (SD) 25.33 ± 2.62 25.17 ± 2.85 25.59 ± 2.33 0.610 (26) ns
Positive family history
for BD-II, N (%)
10 (35.7%) 6 (60%) 4 (40%) 0.003 (1) ns
First episode polarity
(depressive/hypomanic)
24 (85.7%)/4 (14.3%) 14 (82.4%)/3 (17.6%) 10 (90.9%)/1 (9.1%) 0.399 (1) ns
Reported number of depressive
episodes (previous 5 years)*
None, N = 16 (57.1%)
#3, N = 10 (35.7%)
$4, N = 2 (7.1%)
None, N = 9 (52.9%)
#3, N = 7 (41.2%)
$4, N = 1 (5.9%)
None, N = 7 (63.9%)
#3, N = 3 (27.3%)
$4, N = 1 (9.1%)
0.591 (2) ns
Duration of current depressive
episode days (SD); (range)
25.64 ± 18.54; (14–90) 26.18 ± 21.59; (14–90) 24.82 ± 13.47; (14–60) 10.781 (10) ns
HAM-D-17 score (SD); (range) 25.86 ± 3.19; (19–31) 26.53 ± 2.76; (21–31) 24.82 ± 3.65; (19–31) 14.374 (10) ns
YMRS score (SD) 3.46 ± 1.57 3.41 ± 1.73 3.54 ± 1.37 3.544 (6) ns
PSQI score (SD) 11.39 ± 5.31 10.70 ± 4.62 12.45 ± 6.33 12.453 (12) ns
CGI-BP-S (SD) 4.36 ± 1.37 3.94 ± 1.14 5 ± 1.48 5.372 (6) ns
Lifetime axis-I co-morbidity, N (%)
Generalized anxiety disorder 6 (21.4%) 4 (23.5%) 2 (18.2%) 0.113 (1) ns
Obsessive-compulsive disorder 7 (25%) 3 (17.6%) 4 (36.4%) 1.248 (1) ns
Panic disorder 5 (17.9%) 3 (17.6%) 2 (18.2%) 0.001 (1) ns
Specic phobias 8 (26.6%) 4 (23.3%) 4 (36.4%) 0.539 (1) ns
Impulse control disorder 4 (14.3%) 3 (17.6%) 1 (9.1%) 0.399 (1) ns
Anorexia nervosa 1 (3.6%) 1 (5.9%) 0 0.671 (1) ns
Bulimia nervosa 3 (10.7%) 2 (11.8%) 1 (9.1%) 0.050 (1) ns
Binge eating disorder 4 (14.3%) 3 (17.6%) 1 (9.1%) 0.399 (1) ns
Notes: For χ2 and relative, P-values refer to the comparison between the two groups, not versus the whole sample (+valproate vs +lithium). “Age at rst diagnosis of BD”
may differ from age at rst medical consultation for major depression or from actual age of onset of BD. *Current MDE excluded.
Abbreviations: BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item;
MDE, major depressive episode; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation; YMRS, Young Mania Rating Scales.
Table 2 Comparison of clinical measures at week-6 of the study (last post-baseline value)
Included set
N = 28
+valproate group
N = 17 (60.7%)
+lithium group
N = 11 (39.3%)
F or χ2
(df = 2)
P
HAM-D-17 mean score (SD) 10.71 (4.52) 10.23 (3.99) 11.45 (5.35) 11.58 (12) ns
YMRS mean score (SD) 7.89 (5.14) 6.94 (3.38) 9.36 (7.01) 10.531 (8) ns
BMI score, mean (SD) 25.27 (3.26) 25.59 (3.21) 24.77 (3.43) 16.610 (15) ns
CGI-BP-S mean (SD) 4.18 (1.28) 3.82 (1.13) 4.73 (1.35) 4.742 (5) ns
CGI-BP-I mean (SD) 2.78 (1.64) 2.88 (1.87) 2.64 (1.29) 2.306 (6) ns
PSQI mean (SD) 4.61 (1.42) 4.88 (1.41) 4.18 (1.40) 3.835 (5) ns
Abbreviations: BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item;
PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation; YMRS, Young Mania Rating Scales.
observed in the intent to treat population (24.32 ± 2.26 vs
baseline 25.33 ± 2.62) regardless of the primary mood sta-
bilizer treatment. Specifically, mean BMI scores at week
36 were 24.73 ± 2.12 among valproate treated subjects and
23.68 ± 2.43 among lithium treated subjects. Also, at week
36, there was a trend toward a negative correlation between
BMI and HAM-D-17 score (r = –0.16; P = ns). There was
no correlation between BMI and PISQ (r = –0.06; P = ns).
Additional information about the trend of specific clinical
variables within the trial is reported in Figure 1.
Adverse events
Four patients (14.28% of the total) dropped out due to a
treatment-related AE by week 6. In the valproate group, these
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
246
Fornaro et al
Neuropsychiatric Disease and Treatment 2013:9
CGI_BP_I_36
CGI_BP_I_W6
PSQI_W36
CGI_BP_SW36
YMRS_baseline
CGI_BP_S_W6
CGI_BP_S_baseline
PSQI_W6
HAM_D_17_W36
YMRS_W36
YMRS_W36
HAM_D_17_W6
PSQI_baseline
BMI_week_36
BMI_week_6
BMI_baseline
HAM_D_17_baseline
0.00
Lithium
Valproate
10.0020.00
Mean score
Assigned mood-stabilizer
30.00
Figure 1 Trend of different rating and clinical parameters at weeks 6 and 36 between the two groups.
Note: While the gure fails to show any substantial differences between groups, this highlights the fact that the effect of agomelatine add-on therapy was substantially
maintained within week 6 and week 36, independent of the ongoing mood stabilizer treatment.
Abbreviations: BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item;
PSQI, Pittsburgh Sleep Quality Index; YMRS, Young Mania Rating Scales.
included a single case each of pseudo-vertigo and hypomania;
in the lithium group, these included a single case of insomnia
and mania (YMRS = 30).
Two additional cases left the study at week 36 due to
hypomania. These included one each in both the valproate
(YMRS = 17) and lithium (YMRS = 16) treated groups.
Notably, whenever an AE occurred, this was judged as severe
and considered responsible for drop out.
Discussion
Overview and limits of the study
Our results suggest that adjunctive agomelatine may be useful
in the treatment of acute depression in BD-II. During both
the short- and longer-term periods of the trial, agomelatine
treatment was associated with improvements in depression
and sleep quality and was well tolerated.
Nonetheless, the study was limited by several important
factors that warrant discussion, especially in light of the
potential “publication and outcome reporting” biases that
have arisen regarding randomized controlled studies involv-
ing agomelatine in the treatment of MDD.29
Additionally, the pharmacodynamics of agomelatine
need to be better characterized in human samples. In fact,
by inhibiting 5-HT2C receptors, agomelatine secondarily
increases norepinephrine and dopamine in the frontal cortex
of the brain of animals, while the drug binding and coupling
profiles of h5-HT2B and h5-HT2C receptors are similar, and
agomelatine also blocked 5-HT-induced [3H]PI depletion
at h5-HT2B sites.30 However, 5-HT2B receptors are poorly
represented in the central nervous system, wherein their
functional significance remains substantially obscure.31
Due to safety reasons and the preliminary nature of the
study, raters also participated in the clinical management
and were therefore not blind to treatment assignments
(“measurement bias”). Moreover, because agomelatine is
not yet supplied for free by the National Health System in
Italy (unlike many medications), this naturalistic study may
suffer from an additional selection bias, favoring recruitment
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
247
Agomelatine adjunct in acute BD-II depression
Neuropsychiatric Disease and Treatment 2013:9
of patients who were more financially stable and/or motivated
for treatment, potentially influencing both the drop-out rate
and medication adherence (“under/over-reporting bias”),
especially in the optional 30 week extension period. Despite
these limitations, our results should stimulate further inves-
tigation of agomelatine and BD-II.
On the other hand, since the ultimate goal of treatment in
“acute” bipolar depression should be establishing long-term
mood stability,32 the lack of additional follow up, ideally
beyond 52 weeks,11 needs to be noted, although very few
pilot studies would indeed follow this criterion. However, it
is worthy of notice that during both the acute and extension
periods of the trial, adjunctive agomelatine treatment was
associated with improvement in depression, with favorable
safety and tolerability profiles, including sensitive issues such
as liver (there was no clinically relevant enzyme modification
within the trial) and sexual function,29,33,34 although these lat-
ter outcomes were not assessed by ad hoc instruments, and
improvement of subjective sleep quality – when initially
impaired – was not assessed by actigraphic techniques or
by other objective neurophysiological measurements due to
the very preliminary nature of the study, whereas lithium or
valproate may have contributed both to the antidepressant
response and, possibly, to modulation of MT1/MT2 melaton-
ergic receptors as already documented in animal models.35,36
Finally, the fact that the mean duration of depression was
less than 4 weeks (with a lower range of 2 weeks) cannot
exclude the chance of spontaneous improvement due to
the natural course of depression for those subjects judged
as “responders”; equally, the eventual predictive role of
anxious co-morbidity (when present) could not be evinced
at this time due to the small sample size and methodological
limits of this preliminary study, although agomelatine has
been anecdotally reported to have a promising modulating
role in anxious disorders.37–43
Agomelatine, sleep, and depression
The effects of agomelatine on sleep have already been
documented by different studies on MDD samples. Among
others, a comparative study with venlafaxine highlighted a
statistically significant improvement of sleep with agomela-
tine,44 a faster improvement of the “circadian rest-activity
cycle” compared to sertraline,45 and a better rapid eye move-
ment profile – but not short wave sleep profile, possibly due
to 5-HT2C antagonism in comparison to escitalopram,46
although the degree to which 5-HT2C receptor antagonism
explains or contributes to the antidepressant or sleep effect
of agomelatine has been questioned in humans.47
Sleep disturbances are a core aspect of BD and may
often predict subsequent manic switch.48 In our study and
in others, agomelatine led to sustained subjective improve-
ments in sleep quality in association with either lithium or
valproate, beginning as early as 2 weeks into treatment.
The concomitant use of benzodiazepines during the first
2 weeks may have influenced these results, but is unlikely
to account for the effect since only a minority patients used
these medications (n = 3/28; 10.7%), and no patients used
them beyond the second week. Improved sleep quality may
have important clinical implications for BD-II, but may
not necessarily improve mood.49 While insomnia has been
reported as a major predictor of depression,50 abnormalities
in sleep architecture, including disturbances of sleep consoli-
dation, slow-wave sleep, and rapid eye movement sleep are
common during antidepressant treatments, suggesting sleep
quality and mood state are dissociable.51,52 Paradoxically,
four patients (14.3%) experienced insomnia while taking
agomelatine. This problem was effectively managed after
exclusion from the study by switching the time of agomela-
tine administration from bedtime to early morning, without
any subsequent manic switch. While not described in previous
trials, this unexpected insomnia may be related to circadian
phase abnormalities associated with depression. In seasonal
depression, most patients are thought to be phase delayed and
respond to the phase advancing effects of evening melatonin.
In contrast, ∼30% may be phase advanced.53 In these latter
cases, evening melatonin receptor stimulation may lead to a
worsening of the circadian abnormality by further advancing
phase, perhaps disrupting sleep onset and causing nighttime
insomnia. If these findings generalize to bipolar depression,
among the minority of subjects with advanced phase, morn-
ing agomelatine would correct the abnormality by delaying
phase to a more optimal time.
Adverse events and manic switch
While relatively few in number, our study did have AEs to
report, including four mood switches to (hypo-) mania. The
rate of manic/hypomanic switch was lower than expected
based on previous clinical experience with other antidepres-
sants added to mood stabilizers in the treatment of acute
depression in BD-II, yet was still remarkable compared to
other established antidepressants.54 Nonetheless, the profile
of agomelatine with regard to manic switching is consistent
with preliminary reports from BD-I;10 since the safety of
antidepressants in bipolar depression is of great interest in
modern clinical psychiatry, further research on this issue is
needed for agomelatine to reliably compare corresponding
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
248
Fornaro et al
Neuropsychiatric Disease and Treatment 2013:9
data coming from controlled trials on other antidepressants,
ideally looking at long-term treatment compliance and
stability.55
The occurrence of “pseudo-vertigo” (dizziness not
involving a sense of rotation, which is common in the
course of panic disorders, hyperventilation, and orthostatic
hypotension) in three patients was another unexpected AE
that was encountered. Of note, a previous case report sug-
gested an interaction between agomelatine and the melaton-
ergic neurons of the cerebellum in a minority of sensitive
individuals.38 Larger studies are required to determine the
rate of AE associated with this problem.
Implications for the circadian rhythm
hypothesis of BD
With the associated disruptions in sleep and daily activity
cycles, circadian rhythm abnormalities have been proposed
to play a role in the etiology of mood disorders, including
BD. Both lithium and valproate, the mood stabilizers used in
our study, have effects on circadian rhythms,56–58 and genetic
variants in clock genes have been associated with lithium
response.59 BD patients have been reported to be particularly
sensitive to environmental events,60,61 a feature that has also
been associated with circadian instability,62 suggesting that
biological rhythms play a critical role in the emotional dys-
regulation at the center of BD.19,63,64 Central to the circadian
effects on mood is the availability of light. Differential
outcomes in antidepressant response are associated with
specific changes in retinal physiology, suggesting that proper
timing of light input into the central nervous system may be
an important aspect of antidepressant response.65
In this context, it is interesting to consider the implica-
tions of our agomelatine findings with respect to the circadian
clock hypothesis of mood disorders. We found changes in
sleep quality and BMI, the latter presumably reflecting
differences in dietary intake and/or motor activity. It is
interesting to note that regardless of the use of drugs that
affect the clock in distinct ways (lithium and valproate), the
effects of agomelatine on rhythmically influenced behaviors
did not differ by the concomitant mood stabilizer. Of inter-
est, previous reports have described melatonergic neurons
outside the central nervous system, including those in the
gastrointestinal tract, that are influenced both by light/dark
cycles and environmental stressors.66–69 Collectively, these
findings lend support to the supposed interaction between
melatonergic regulation on mood and the “gut-clock”.70
If further evidence supports the hypothesis that agomela-
tine functions as core “rhythm regulator,”71 it could play
a therapeutic role for those BD patients with prominent
imbalances in eating rhythms, and may extend the concept
of rhythm disturbances in mood disorder to include feeding
behavior and metabolic activity in addition to sleep/wake
behavior.72–75 This could be in marked contrast to standard
antidepressants, with their propensity toward causing weight
gain via serotonergic stimulation of 5-HT2A receptors
rather than selective antagonism of 5-HT2C.9,51,76,77 It will be
of interest in the future to determine whether agomelatine
affects excessive or atypical eating behaviors in the context
of depression, especially in the view that animal studies have
reported that 5-HT2B agonists concur with hyperphagia and
reduce grooming in rodents,78 whereas stimulation of 5-HT2B
sites exerts actions in animal peripheral tissues, especially in
development. However, there is no evidence for a functional
effect of antagonists at these sites79 and agomelatine is yet to
be characterized in this regard in human samples.
Concluding remarks
Adjunctive agomelatine treatment with lithium or valproate
in the acute phase of BD-II major depression led to substan-
tial positive results in our preliminary open label trial. Large
double-blind randomized controlled studies are warranted
and will be essential to providing more definitive evidence of
the efficacy, safety, and optimal dose-range profile compared
to MDD usage.80
Disclosure
The authors report no conflicts of interest in this work.
References
1. APA. Diagnostic and Statistical Manual for Mental Disorders, 4th ed.
Washington, DC: American Psychiatric Association; 1994.
2. Ketter TA, Calabrese JR. Stabilization of mood from below versus above
baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002;
63(2):146–151.
3. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipo-
lar II depression: current evidence. The Journal of Clinical Psychiatry.
2011;72(3):356–366.
4. Rybakowski JK. Bipolarity and inadequate response to antidepressant
drugs: clinical and psychopharmacological perspective. Journal of Affec-
tive Disorders. 2012;136(1–2):e13–e19.
5. Fornaro M, Martino M, De Pasquale C, Moussaoui D. The argument
of antidepressant drugs in the treatment of bipolar depression: mixed
evidence or mixed states? Expert Opinion on Pharmacotherapy.
2012;13(14):2037–2051.
6. den Boer JA, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in
depression: the evidence. International Clinical Psychopharmacology.
2006;21(Suppl 1):S21–S24.
7. Montgomery SA, Kasper S. Severe depression and antidepressants:
focus on a pooled analysis of placebo-controlled studies on agomelatine.
International Clinical Psychopharmacology. 2007;22(5):283–291.
8. Kennedy SH, Young AH, Blier P. Strategies to achieve clinical effective-
ness: refining existing therapies and pursuing emerging targets. Journal
of Affective Disorders. 2011;132(Suppl 1):S21–S28.
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
249
Agomelatine adjunct in acute BD-II depression
Neuropsychiatric Disease and Treatment 2013:9
9. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated
review on the antidepressant agomelatine focusing on its melatonergic
modulation. Current Neuropharmacology. 2010;8(3):287–304.
10. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunc-
tive therapy for acute bipolar depression: preliminary open data. Bipolar
Disorders. 2007;9(6):628–635.
11. Eppel AB. Agomelatine adjunctive therapy for acute bipolar depression:
preliminary open data. Bipolar Disorders. 2008;10(6):749–750.
12. Angst J, Marneros A. Bipolarity from ancient to modern times: concep-
tion, birth and rebirth. Journal of Affective Disorders. 2001;67(1–3):
3–19.
13. Lopez-Munoz F, Alamo C. Cartesian theories on the passions, the pineal
gland and the pathogenesis of affective disorders: an early forerunner.
Psychological Medicine. 2011;41(3):449–451.
14. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by
tricyclic antidepressants. Archives of General Psychiatry. 1979;36(5):
555–559.
15. McCarthy MJ, Welsh DK. Cellular circadian clocks in mood disorders.
Journal of Biological Rhythms. 2012;27(5):339–352.
16. Jackson A, Cavanagh J, Scott J. A systematic review of manic and
depressive prodromes. Journal of Affective Disorders. 2003;74(3):
209–217.
17. Monteleone P, Martiadis V, Maj M. Circadian rhythms and treatment
implications in depression. Progress in Neuro-Psychopharmacology
and Biological Psychiatry. 2011;35(7):1569–1574.
18. Racagni G, Riva MA, Molteni R, et al. Mode of action of agomelatine:
synergy between melatonergic and 5-HT2C receptors. The world journal
of biological psychiatry. The Official Journal of the World Federation
of Societies of Biological Psychiatry. 2011;12(8):574–587.
19. Murray G, Harvey A. Circadian rhythms and sleep in bipolar disorder.
Bipolar Disorders. 2010;12(5):459–472.
20. Mazza M, Mandelli L, Martinotti G, et al. Further evidence supporting
the association between 5HTR2C gene and bipolar disorder. Psychiatry
Research. 2010;180(2–3):151–152.
21. Fornaro M, Aguglia E, Dell’Osso L, Perugi G. Could the underestima-
tion of bipolarity obstruct the search for novel antidepressant drugs?
Expert Opinion on Pharmacotherapy. 2011;12(18):2817–2831.
22. First MB, Spitzer RI, Gibbon M, Williams BJW. Structured Clinical
Interview for DSM-IV Axis I Disorders. Washington, DC: American
Psychiatric Press; 1997.
23. Hamilton M. Development of a rating scale for primary depres-
sive illness. The British Journal of Social and Clinical Psychology.
1967;6(4):278–296.
24. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modi-
fication of the Clinical Global Impressions (CGI) Scale for use in
bipolar illness (BP): the CGI-BP. Psychiatry Research. 1997;73(3):
159–171.
25. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania:
reliability, validity and sensitivity. The British Journal of Psychiatry:
The Journal of Mental Science. 1978;133:429–435.
26. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ.
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric
practice and research. Psychiatry Research. 1989;28(2):193–213.
27. Julious SA. Sample size of 12 per group rule of thumb for a pilot study.
Pharmaceutical Statistics. 2005;4(4):287–291.
28. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moder-
ate and severe depression using the Montgomery-Asberg Depression
Rating Scale (MADRS). Journal of Affective Disorders. 2003;77(3):
255–260.
29. Howland RH. Publication bias and outcome reporting bias: agomelatine
as a case example. Journal of Psychosocial Nursing and Mental Health
Services. 2011;49(9):11–14.
30. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist
agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C
receptors, blockade of which enhances the activity of frontocortical
dopaminergic and adrenergic pathways. The Journal of Pharmacology
and Experimental Therapeutics. 2003;306(3):954–964.
31. Duxon MS, Kennett GA, Lightowler S, Blackburn TP, Fone KC.
Activation of 5-HT2B receptors in the medial amygdala causes
anxiolysis in the social interaction test in the rat. Neuropharmacology.
1997;36(4–5):601–608.
32. Malhi GS, Adams D, Berk M. Medicating mood with maintenance
in mind: bipolar depression pharmacotherapy. Bipolar Disorders.
2009;11(Suppl 2):55–76.
33. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I.
Absence of discontinuation symptoms with agomelatine and occurrence
of discontinuation symptoms with paroxetine: a randomized, double-
blind, placebo-controlled discontinuation study. International Clinical
Psychopharmacology. 2004;19(5):271–280.
34. Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomela-
tine on sexual function in depressed patients and healthy volunteers.
Human Psychopharmacology. 2011;26(8):537–542.
35. Niles LP, Sathiyapalan A, Bahna S, Kang NH, Pan Y. Valproic acid up-
regulates melatonin MT1 and MT2 receptors and neurotrophic factors
CDNF and MANF in the rat brain. The International Journal of Neuro-
psychopharmacology/Official Scientific Journal of the Collegium Inter-
nationale Neuropsychopharmacologicum. 2012;15(9):1343–1350.
36. Hallam KT, Olver JS, Horgan JE, McGrath C, Norman TR. Low doses
of lithium carbonate reduce melatonin light sensitivity in healthy
volunteers. The International Journal of Neuropsychopharmacology/
Official Scientific Journal of the Collegium Internationale
Neuropsychopharmacologicum. 2005;8(2):255–259.
37. Levitan MN, Papelbaum M, Nardi AE. A review of preliminary observa-
tions on agomelatine in the treatment of anxiety disorders. Experimental
and Clinical Psychopharmacology. 2012;20(6):504–509.
38. Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine
in patients with refractory obsessive-compulsive disorder: a 3 month
follow-up case series. Annals of General Psychiatry. 2011;10(1):5.
39. Fornaro M. Agomelatine in the treatment of panic disorder. Progress
in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(1):
286–287.
40. De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of
escitalopram therapy in treatment-resistant obsessive-compulsive disor-
der: a case report. Case Reports in Psychiatry. 2012;2012:642–752.
41. De Berardis D, Serroni N, Campanella D, et al. A case of obsessive-com-
pulsive disorder successfully treated with agomelatine monotherapy.
Journal of Clinical Psychopharmacology. 2012;32(2):289–290.
42. De Berardis D, Serroni N, Marini S, Moschetta FS, Martinotti G,
Di Giannantonio M. Agomelatine for the treatment of posttraumatic stress
disorder: a case report. Annals of Clinical Psychiatry: Official Journal of
the American Academy of Clinical Psychiatrists. 2012;24(3):241–242.
43. Crippa JA, Hallak JE, Zuardi AW, Chagas MH, Quevedo J, Nardi AE.
Agomelatine in the treatment of social anxiety disorder. Progress in
Neuro-Psychopharmacology and Biological Psychiatry. 2010;34(7):
1357–1358.
44. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective
sleep in major depressive disorder with a novel antidepressant, ago-
melatine: randomized, double-blind comparison with venlafaxine. The
Journal of Clinical Psychiatry. 2007;68(11):1723–1732.
45. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepres-
sant agomelatine on the circadian rest-activity cycle and depressive
and anxiety symptoms in patients with major depressive disorder: a
randomized, double-blind comparison with sertraline. The Journal of
Clinical Psychiatry. 2010;71(2):109–120.
46. Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomela-
tine and escitalopram on nighttime sleep and daytime condition and
efficacy in major depressive disorder patients. International Clinical
Psychopharmacology. 2011;26(5):252–262.
47. Sharpley AL, Rawlings NB, Brain S, McTavish SF, Cowen PJ. Does
agomelatine block 5-HT2C receptors in humans? Psychopharmacology.
2011;213(2–3):653–655.
48. Colombo C, Benedetti F, Barbini B, Campori E, Smeraldi E. Rate of
switch from depression into mania after therapeutic sleep deprivation
in bipolar depression. Psychiatry Research. 1999;86(3):267–270.
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
250
Fornaro et al
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing
on concise rapid reporting of clinical or pre-clinical studies on a
range of neuropsychiatric and neurological disorders. This journal
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS.
The manuscript management system is completely online and includes
a very quick and fair peer-review system, which is all easy to use. Visit
http://www.dovepress.com/testimonials.php to read real quotes from
published authors.
Neuropsychiatric Disease and Treatment 2013:9
49. Rojo JE, Gibert K, Cobo J, Rodriguez-Cano E, Vallejo J. Onset
of antidepressant action: a pharmacological question? Human
Psychopharmacology. 2005;20(6):425–433.
50. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of
depression: a meta-analytic evaluation of longitudinal epidemiological
studies. Journal of Affective Disorders. 2011;135(1–3):10–19.
51. Matthews PR. Efficacy of antidepressants: similar but different. The
International Journal of Neuropsychopharmacology/Official Scientific
Journal of the Collegium Internationale Neuropsychopharmacologicum.
2011;14(10):1433–1437.
52. Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant
treatment. Current Pharmaceutical Design. 2012;18(36):5802–5817.
53. Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter
depression. Proceedings of the National Academy of Sciences of the
United States of America. 2006;103(19):7414–7419.
54. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood
polarity to hypomania or mania in patients with bipolar depression
during acute and continuation trials of venlafaxine, sertraline, and
bupropion as adjuncts to mood stabilizers. The American Journal of
Psychiatry. 2006;163(2):232–239.
55. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discon-
tinuation in bipolar depression: a Systematic Treatment Enhancement
Program for Bipolar Disorder (STEP-BD) randomized clinical trial of
long-term effectiveness and safety. The Journal of Clinical Psychiatry.
2010;71(4):372–380.
56. Kripke DF, Judd LL, Hubbard B, Janowsky DS, Huey LY. The effect
of lithium carbonate on the circadian rhythm of sleep in normal human
subjects. Biological Psychiatry. 1979;14(3):545–548.
57. Li J, Lu WQ, Beesley S, Loudon AS, Meng QJ. Lithium impacts on
the amplitude and period of the molecular circadian clockwork. PloS
One. 2012;7(3):e33292.
58. Johansson AS, Brask J, Owe-Larsson B, Hetta J, Lundkvist GB. Valproic
acid phase shifts the rhythmic expression of Period2::Luciferase.
Journal of Biological Rhythms. 2011;26(6):541–551.
59. McCarthy MJ, Nievergelt CM, Shekhtman T, Kripke DF, Welsh DK,
Kelsoe JR. Functional genetic variation in the Rev-Erbalpha pathway
and lithium response in the treatment of bipolar disorder. Genes, Brain,
and Behavior. 2011;10(8):852–861.
60. Gruber J, Miklowitz DJ, Harvey AG, et al. Sleep matters: sleep func-
tioning and course of illness in bipolar disorder. Journal of Affective
Disorders. 2011;134(1–3):416–420.
61. Scott J. Clinical parameters of circadian rhythms in affective disorders.
European Neuropsychopharmacology: The Journal of the European
College of Neuropsychopharmacology. 2011;21(Suppl 4):S671–S675.
62. Murray G, Allen NB, Trinder J, Burgess H. Is weakened circadian rhyth-
micity a characteristic of neuroticism? Journal of Affective Disorders.
2002;72(3):281–289.
63. Bullock B, Judd F, Murray G. Social rhythms and vulnerability to bipo-
lar disorder. Journal of Affective Disorders. 2011;135(1–3):384–388.
64. Ehlers CL, Frank E, Kupfer DJ. Social zeitgebers and biological
rhythms. A unified approach to understanding the etiology of depres-
sion. Archives of General Psychiatry. 1988;45(10):948–952.
65. Fornaro M, Bandini F, Ogliastro C, et al. Electroretinographic assess-
ment in major depressed patients receiving duloxetine: might differ-
ences between responders and non-responders indicate a differential
biological background? Journal of Affective Disorders. 2011;135(1–3):
154–159.
66. Konturek PC, Brzozowski T, Konturek SJ. Gut clock: implication of
circadian rhythms in the gastrointestinal tract. Journal of Physiology
and Pharmacology: An Official Journal of the Polish Physiological
Society. 2011;62(2):139–150.
67. Nisembaum LG, Velarde E, Tinoco AB, et al. Light-dark cycle
and feeding time differentially entrains the gut molecular clock
of the goldfish (Carassius auratus). Chronobiology International.
2012;29(6):665–673.
68. Huang W, Ramsey KM, Marcheva B, Bass J. Circadian rhythms, sleep,
and metabolism. The Journal of Clinical Investigation. 2011;121(6):
2133–2141.
69. Reiter RJ, Rosales-Cor ral S, Coto-Montes A, et al. The photoperiod,
circadian regulation and chronodisruption: the requisite interplay
between the suprachiasmatic nuclei and the pineal and gut melatonin.
Journal of Physiology and Pharmacology: An Official Journal of the
Polish Physiological Society. 2011;62(3):269–274.
70. Albrecht U. Circadian rhythms and sleep – the metabolic connection.
Pflugers Archiv: European Journal Of Physiology. 2012;463(1):
23–30.
71. Fountoulakis KN. Disruption of biological rhythms as a core problem
and therapeutic target in mood disorders: the emerging concept of
‘rhythm regulators’. Annals of General Psychiatry. 2010;9:3.
72. Fornaro M, Perugi G, Gabrielli F, et al. Lifetime co-morbidity with
different subtypes of eating disorders in 148 females with bipolar
disorders. Journal of Affective Disorders. 2010;121(1–2):147–151.
73. Muhlhans B, Olbrich K, de Zwaan M. Night eating syndrome and
nocturnal eating – what is it all about? Psychotherapie, Psychosomatik,
Medizinische Psychologie. 2009;59(2):50–56.
74. Goel N, Stunkard AJ, Rogers NL, et al. Circadian rhythm profiles in
women with night eating syndrome. Journal of Biological Rhythms.
2009;24(1):85–94.
75. McElroy SL, Frye MA, Hellemann G, et al. Prevalence and correlates
of eating disorders in 875 patients with bipolar disorder. Journal of
Affective Disorders. 2011;128(3):191–198.
76. Montgomery SA. Why do we need new and better antidepressants?
International Clinical Psychopharmacology. 2006;21(Suppl 1):
S1–S10.
77. Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, Quera-
Salva MA. Antidepressant efficacy of agomelatine versus SSRI/SNRI:
results from a pooled analysis of head-to-head studies without a placebo
control. International Clinical Psychopharmacology. 2012;28(1):
12–9.
78. Kennett GA, Ainsworth K, Trail B, Blackburn TP. BW 723C86, a
5-HT2B receptor agonist, causes hyperphagia and reduced grooming
in rats. Neuropharmacology. 1997;36(2):233–239.
79. Nebigil CG, Etienne N, Schaerlinger B, Hickel P, Launay JM,
Maroteaux L. Developmentally regulated serotonin 5-HT2B receptors.
International Journal of Developmental Neuroscience: The Official
Journal of the International Society for Developmental Neuroscience.
2001;19(4):365–372.
80. Loo H, Hale A, D’Haenen H. Determination of the dose of agomela-
tine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in
the treatment of major depressive disorder: a placebo-controlled dose
range study. International Clinical Psychopharmacology. 2002;17(5):
239–247.
submit your manuscript | www.dovepress.com
Dovepress
Dovepress
Dovepress
251
Agomelatine adjunct in acute BD-II depression